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Bioassay-guided fractionation of dichloromethane
extracts of Cyrtanthus suaveolens using the
Salmonella/microsome assay (strain TA98) led to the iso-
lation of captan [N-(trichloromethylthio)cyclohex-4-ene-
1,2-diccarboximide] at a concentration of 100mg kg–1 of
dry plant material. Captan is a pesticide used on a large
scale on agricultural and horticultural crops. It is known
for its mutagenic, genotoxic and teratogenic effects.
Issues of quality and safety of traditional medicinal
plants grown commercially in South Africa and the need
for the establishment of good agricultural practices are
discussed.
Cancer is one of five major causes of death in developed
countries (Rang et al. 1995). The most common causes of
cancer are from environmental effects and exposure to cer-
tain chemical compounds. These include insufficiently test-
ed medicine, environmental pollutants and food contami-
nants (Pozharskii et al. 1997). Tremendous care is taken in
the monitoring of environmental pollutants, food additives,
pharmaceutical products and various chemicals of agricul-
tural importance such as pesticides for possible carcino-
genic and/or mutagenic effects (Pozharskii et al. 1997).
These efforts result in the withdrawal of many products
whether of nutritional, pharmaceutical or agricultural impor-
tance from the market especially in the developed countries.
Plants used in traditional medicine provide primary health
care to the majority of people in developing countries
(Addae-Mensah 1992). These plants are presumed to be
safe due to their long-term use for the treatment of various
ailments, by different ethnic groups. However, research
showed that crude extracts of plants used in traditional med-
icine are a source of potential carcinogens (De Sá and
Ferr|o Vargas 1999). These plants need to be thoroughly
investigated, in the interests of patient safety.
A recent study on the mutagenic effects of some plants
used in South African traditional medicine revealed muta-
genicity of different parts of Cyrtanthus falcatus and C.
suaveolens in the Salmonella/microsome assay
(strainTA98) (Elgorashi and Van Staden 2004). The primary
objective of this study was to isolate the mutagenic com-
pound(s) from the crude extracts of C. suaveolens.
However, the isolation of Captan, a known fungicide, from
the plant extracts raises the importance of issues of quality
and safety of medicinal plants produced commercially for the
South African market and the need for good agricultural
practices to be established.
Material and Methods
Plant material
Plants of C. suaveolens were obtained from Green Goblen
Nursery, Durban. A voucher specimen (Elgorashi NU6) was
deposited at the Herbarium of the University of Natal
Pietermaritzburg. Mr G Duncan, of the National Botanical
Institute, confirmed the identity of the plants extracted.
Extraction and isolation
Extraction and isolation were achieved by bioassay-guided
processes using Salmonella typhimurium TA98. Dried (oven
at 55°C) and powdered underground parts (bulbs/roots) of
C. suaveolens (250g) were extracted with dichloromethane
(1.25l x 2) for 24h to give 3.13g of crude extract. The crude
extract was fractionated using a column packed with silica
gel 60 (70–230 mesh). The column was eluted with hexane
and then with hexane mixed gradually with 1%, 2%, 5%,
10%, 12%, 20%, 40%, 50% and 60% ethyl acetate, ending
with 100% ethyl acetate.
Fractions of 20ml were collected and examined using thin
layer chromatography. Fractions of similar content were com-
bined and tested for mutagenic effects. Fractions 128–137
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(672mg) were combined and developed on a column using
silica gel eluted with the same solvent systems. Fractions of
20ml were collected. Fractions 98–124 were combined
(200mg) and developed on silica gel 60 F254 preparative thin
layer chromatography plates (2mm) using hexane:
dichloromethane:methanol (14:8:1) to give captan (25mg).
Mutagenicity assay
A mutagenicity test was carried out using the
Salmonella/microsome assay based on the plate-incorpora-
tion procedure with Salmonella typhimurium tester strain
TA98. The assay was performed according to Maron and
Ames (1983). Stock (100µl) bacteria in 20ml Oxoid nutrient
broth No. 2 were incubated for 16h at 37°C. The bacterial
cultures (100µl) were added to 100µl of the plant extract in
500ml phosphate buffer and 2ml of agar containing biotin-
histidine (0.5mM). The mixture was poured onto a minimal
agar plate and incubated at 37°C for 48h. 4-Nitroquinoline-
N-oxide (4 NQO) was used as a positive control at a con-
centration of 2µg ml–1. Samples were tested in triplicate with
two replicates. Three dilutions were prepared per sample.
Results and Discussion
Bioassay-guided fractionation of the crude extracts of C.
suaveolens using the Salmonella/microsome assay led to
the isolation of captan (Figure 1). Its NMR and EIMS data
are in agreement with those reported for captan (Angioni et
al. 2003). Results on the mutagenic effect of captan at dif-
ferent stages of purification are presented in Table 1. Captan
has been used commercially on a large scale, for many
years, in horticulture and agriculture as an antifungal or bac-
teriostatic agent (Bridges 1975). This compound induces
base-pair substitution mutations in Escherichia coli,
Salmonella typhimurium, Neurospora crassa and Chinese
hamster cells. It also causes gene conversion in
Saccharomyces cervisiae, chromatid breaks in heteroploid
human embryonic lung cells and lethal mutations in rats and
mice (Ficsor et al. 1977, Vigfusson and Vyse 1980).
The use of herbal medicine in seeking cures from illness
can be traced back over five millennia to documents pro-
duced by early civilizations worldwide (Hamburger and
Hostettmann 1991). In South Africa and most developing
countries traditional medicine still forms the backbone of
rural medical practice. About 3 000 plant species are used
as medicine in South Africa alone and of these about 350
species are commonly used and traded in large volumes
(Van Wyk et al. 1997). The majority of these plants have
been and, where still possible, are harvested from wild pop-
ulations within South Africa and neighbouring countries. This
results in their overexploitation. To add to this problem of
overexploitation, a large proportion (±85%) of the plant
material traded consists of non-renewable material, material
which when harvested either severely damages the plant or
kills it, such as bulbs, rhizomes and bark (Mander 1997).
This excessive pressure on wild plant populations had
resulted in many species becoming extremely rare and even
nonexistent outside protected areas. Heavy exploitation of
Warburgia salutaris, Cassine transvaalensis, Alepidea
amatymbica and Erythrophleum lasianthum were recorded
as early as 1938 (Gerstner 1941). It is clear that with the
existing demand for medicinal plants sustainable harvesting
is not feasible. If the future demand is to be met, it is essen-
tial that many of the popular species utilised in traditional
medicine be developed for commercial cultivation.
There are two potential solutions, the production of plant
materials by community nurseries or small-scale rural farm-
ers and large-scale production by commercial farmers.
However, before commercial farms can venture into the
propagation of indigenous medicinal plants, cultivation, han-
dling and processing protocols have to be developed.
Cultivation of medicinal plants encompasses a number of
agricultural practices including sowing, irrigation, fertilisa-
tion, pesticide and herbicide application, harvesting and pro-
cessing. These agricultural practices may cause the con-
tamination of plant material with fertilisers and pesticide
residues, which accumulate from application during cultiva-
tion and administration of fumigants during storage.
Medicinal plants can not be grown in soils that are contami-
nated by sludge and heavy metals. Other fertilising agents
Table 1: Number of his+ revertants in Salmonella typhimurium strain TA98 produced by captan at different stages of purification
No. of colonies
Extract No. Extract Concentration (µg ml) +ve control -ve control
5 000 1 000 500 100 50
1 752 ± 39 137 ± 7 29 ± 6 252.6 ± 18.9 21.4 ± 3.9
2 UC 816 ± 31 252 ± 23 179 ± 0.7 24 ± 6.3
3 – 559 ± 20 277 ± 15 35 ± 5 132 ± 13.4 21.8 ± 3.3
Captan 742 ± 79 143 ± 16 31 ± 7 239 ± 8.3 24.7 ± 1.3
Extracts induced revertant colonies numbering at least twice the revertant control number were mutagenic
UC = uncountable colonies


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Figure 1: Chemical structure of captan
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should be applied sparingly and in accordance with the
demands of the plant species. 
Pesticide and herbicide application should be avoided as
far as possible. If their application is inevitable, pesticides
and herbicides application should be according to quality
control methods for medicinal plant materials issued by the
World Health Organization (WHO). These quality control
methods stressed that the toxicological evaluation of pesti-
cide residues in medicinal plant materials should be based
on the likely intake of the material by patients. In general, the
intake of residue from medicinal plant material should
account for not more than 1% of total intake from all sources,
including food and drinking water (WHO 1998).
In South Africa there is little regulation and development of
the medicinal plant trade despite its economic, conserva-
tional and cultural importance. However, there are two
important provisions in the South African Medicines and
Medical Devises Regulatory Bills: the first regulates general
traditional healers in South Africa under the associated
Health Service Professions Act of 1982 as amended. The
regulation entitles medical providers to practice for gain and
call themselves members of that profession. In accordance
with the second, issues of safety and quality take prece-
dence over demonstrations of efficacy (WHO 2001).
Although the above two regulations acknowledge the role
of traditional healers in the health care system and the
importance of safety and quality of plants used in traditional
medicine, they fall short of calling for Good Manufacturing
Practice (GMP), initiated by the WHO in the mid-eighties
with the ultimate aim of ensuring continuous high quality pro-
duction of products for human consumption and the guide-
lines for the good Agricultural Practice of Medicinal and
Aromatic herbs which is intended to apply to the growing
and primary processing of all such plants traded and used in
the European Union (Franz 1989, Schilcher 1989).
If the development of a safe and high quality medicinal
plant industry in South Africa is to occur it is important that
sound guidelines for production, processing and marketing
are developed that can be implemented from the onset.
Some common ground between those currently used in
Europe and the rest of the world and those to be imple-
mented in South Africa should be reached, particularly
where export potential is envisaged.
Above all, if plants are to be cultivated for the South
African traditional market then several cultural aspects have
to be taken into consideration. Conservative traditional heal-
ers believe that plants grown under western agricultural
conditions (i.e. with fertilisers and in straight lines) will not
have the same medicinal properties as those harvested from
the wild. This is a ‘supernatural’ phenomenon and therefore
scientific validation of the biological activity of cultivated
plants will not sway traditional healers beliefs. However, the
dwindling plant numbers coupled with the increased demand
for these plants has resulted in large price increases and
limited supplies of certain species. This means that most
healers are willing to accept that cultivation is the only solu-
tion (Stafford 2003).
This study also raises concern where reporting on bioac-
tivity of plant crude extracts without the isolation and identifi-
cation of the active compounds. The activity of these extracts
might be due to a contaminant, such as pesticide, rather than
a plant product, which may lead to incorrect conclusions.
Acknowledgements — The authors thank the University of
KwaZulu-Natal Research Fund and the National Research
Foundation, Pretoria, for financial support.
References
Addae-Mensah I (1992) Towards a Rational Scientific Basis for
Herbal Medicine — a Phytochemist’s Two-decade Contribution.
Ghana University Press, Accra
Angioni A, Garau VL, Del Real AA, Melis M, Minelli EV, Tuberoso C,
Cabras P (2003) GC-ITMS determination and degradation of
Captan during winemaking. Journal of Agricultural and Food
Chemistry 51: 6761–6766
Bridges BA (1975) The mutagenicity of captan and related fungi-
cides. Mutation Research 32: 3–34
De Sá Ferreira ICF, Ferr|o Vargas VM (1999) Mutagenicity of
medicinal plant extracts in Salmonella/microsome assay.
Phytotherapy Research 13: 397–400
Elgorashi EE, Van Staden J (2004) Pharmacological screening of six
Amaryllidaceae species. Journal of Ethnopharmacology 90: 27–32
Ficsor G, Bordás S, Wade SM, Muthiani E, Wertz GF, Zimmer DM
(1977) Mammalian host- and fluid-mediated mutagenicity assays
of captan and streptozotocin in Salmonella typhimmurium.
Mutation Research 48: 1–16
Franz C (1989) Good agricultural practice (GAP) for medicinal and
aromatic plant production. Acta Horticulturae 249: 125–128
Gerstner J (1941) A preliminary checklist of Zulu names of plant with
short noted. Bantu Studies 15: 277
Hamburger M, Hostettmann K (1991) Bioactivity in plants: the link
between phytochemistry and medicine. Phytochemistry 30:
3864–3874
Mander M (1997) The Marketing of Indigenous Medicinal Plants in
South Africa: A Case Study in KwaZulu-Natal. Institute of Natural
Resources, Pietermaritzburg
Maron DM, Ames BN (1983) Revised methods for the Salmonella
mutagenicity test. Mutation Research 113: 173–215
Pozharskii AF, Soldatenkov AT, Katritzky AR (1997) Heterocycles in
Life and Society. An Introduction to Heterocyclic Chemistry and
Biochemistry and the Role of Heterocycles in Science, Technology,
Medicine and Agriculture. John Wiley & Sons, Chichester
Rang HP, Dale MM, Ritter JM (1995) Pharmacolgy. Churchill
Livingstone, Edinburgh
Schilcher RE (1989) Proposed rules for good agricultural practice.
Acta Horticulturae 249: 123–124
Stafford GI (2003) Storage of Frequently Used Traditional South
African Medicinal Plants. MSc Thesis, University of Natal,
Pietermaritzburg, South Africa
Van Wyk B, Van Oudtshoorn B, Gericke N (1997) Medicinal Plants
of South Africa. Briza Publications, South Africa
Vigfusson NV, Vyse ER (1980) The effect of the pesticides, dexon,
captan and roundup, on sister-chromatid exchanges in human
lymphocytes in vitro. Mutation Research 79: 53–57
World Health Organization (1998) Quality Control Methods for
Medicinal Plant Materials. Geneva, Switzerland
World Health Organization (2001) Legal Status of Traditional
Medicine and Complementary Medicine: A World Wide Review.
Geneva, Switzerland
Edited by AK Jäger
